In a recent study, we demonstrated that bromocriptine-QR treatment in inadequately controlled T2D subjects treated with a glucagon-like peptide 1 receptor agonist (GLP-1RA) improved endothelial dysfunction, reduced blood pressure, and enhanced suppression of post-meal hepatic glucose production without increasing plasma insulin-effects suggestive of reduced SNS tone [104]. This evidence concerns the gene INS and endothelial dysfunction.